Recent findings that inhibitors of mutated isocitrate dehydrogenase (IDH) are associated with clinical and morphological signs of myeloid differentiation revived the interest in differentiation therapy of non-APL AML. This evidence concerns the gene IDH1 and acute myeloid leukemia.